Kestra Medical Technologies (NASDAQ:KMTS) Insider Alfred Ford, Jr. Sells 8,681 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 8,681 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $22.61, for a total value of $196,277.41. Following the completion of the sale, the insider directly owned 118,854 shares of the company’s stock, valued at approximately $2,687,288.94. The trade was a 6.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 5.1%

KMTS stock opened at $23.99 on Tuesday. Kestra Medical Technologies, Ltd. has a 1-year low of $14.10 and a 1-year high of $30.00. The business’s 50 day simple moving average is $22.62 and its 200 day simple moving average is $22.48. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The business had revenue of $28.64 million for the quarter. As a group, research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors have recently modified their holdings of the business. California State Teachers Retirement System grew its stake in shares of Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after acquiring an additional 7,844 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after purchasing an additional 5,731 shares in the last quarter. Quantinno Capital Management LP bought a new stake in Kestra Medical Technologies in the 1st quarter valued at about $431,000. Sei Investments Co. boosted its holdings in Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after purchasing an additional 43,753 shares during the period. Finally, Spartan Wealth Advisory Services LLC bought a new position in shares of Kestra Medical Technologies during the first quarter worth approximately $603,000.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Oppenheimer started coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating for the company. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. BTIG Research raised their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $27.83.

Key Headlines Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.